Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 28;19(5):1318.
doi: 10.3390/ijms19051318.

Exploring microRNA Biomarker for Amyotrophic Lateral Sclerosis

Y-H Taguchi  1 , Hsiuying Wang  2
Affiliations

Exploring microRNA Biomarker for Amyotrophic Lateral Sclerosis

Y-H Taguchi et al. Int J Mol Sci. .

Abstract

Amyotrophic lateral sclerosis (ALS) is among the severe neuro degenerative diseases that lack widely available effective treatments. As the disease progresses, patients lose the control of voluntary muscles. Although the neuronal degeneration is the cause of this disease, the failure mechanism is still unknown. In order to seek genetic mechanisms that initiate and progress ALS, the association of microRNA (miRNA) expression with this disease was considered. Serum miRNAs from healthy controls, sporadic ALS (sALS), familial ALS (fALS) and ALS mutation carriers were investigated. Principal component analysis (PCA)-based unsupervised feature extraction (FE) was applied to these serum miRNA profiles. As a result, we predict miRNAs that can discriminate patients from healthy controls with high accuracy. Thus, these miRNAs can be potential prognosis miRNA biomarkers for ALS.

Keywords: amyotrophic lateral sclerosis; biomarker; microRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of analyses performed in this paper.
Figure 2
Figure 2
The second PC loading, which is associated with adjusted p-valued 2.2 × 10−5.
Figure 3
Figure 3
The first, the third, the fourth and the eighth PC loadings.
Figure 4
Figure 4
The first and second discriminate functions. HC: healthy controls, MU: ALS mutation carrier, F: fALS patients, S: sALS patients. Blue broken lines are only for a guide for eyes in order to emphasize that HC, MU, and F are well separated.
See this image and copyright information in PMC

References

    1. Tiryaki E., Horak H.A. ALS and other motor neuron diseases. Continuum. 2014;20:1185–1207. doi: 10.1212/01.CON.0000455886.14298.a4. - DOI - PubMed
    1. Chen S., Sayana P., Zhang X., Le W. Genetics of amyotrophic lateral sclerosis: An update. Mol. Neurodegener. 2013;8:28. doi: 10.1186/1750-1326-8-28. - DOI - PMC - PubMed
    1. Sau D., De Biasi S., Vitellaro-Zuccarello L., Riso P., Guarnieri S., Porrini M., Simeoni S., Crippa V., Onesto E., Palazzolo I., et al. Mutation of SOD1 in ALS: A gain of a loss of function. Hum. Mol. Genet. 2007;16:1604–1618. doi: 10.1093/hmg/ddm110. - DOI - PubMed
    1. Hirano M., Quinzii C.M., Mitsumoto H., Hays A.P., Roberts J.K., Richard P., Rowland L.P. Senataxin mutations and amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2011;12:223–227. doi: 10.3109/17482968.2010.545952. - DOI - PMC - PubMed
    1. Scotter E.L., Chen H.J., Shaw C.E. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics. 2015;12:352–363. doi: 10.1007/s13311-015-0338-x. - DOI - PMC - PubMed